Synapse - Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC)

Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract

Authors:	Morris, M. J.; Pandit-Taskar, N.; Carrasquillo, J. A.; O'Donoghue, J. A.; Humm, J.; Lyashchenko, S. K.; Haupt, E. C.; Bander, N. H.; Tagawa, S. T.; Holland, J. P.; Smith-Jones, P. M.; Lewis, J. S.; Solomon, S. B.; Scher, H. I.; Larson, S. M.
Abstract Title:	Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC)
Meeting Title:	2013 Genitourinary Cancers Symposium
Journal Title:	Journal of Clinical Oncology
Volume:	31
Issue:	6 Suppl.
Meeting Dates:	2013 Feb 14-16
Meeting Location:	Orlando, FL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2013-02-20
Language:	English
ACCESSION:	WOS:000333679600034
DOI:	10.1200/jco.2013.31.6_suppl.31
PROVIDER:	wos
Notes:	Meeting Abstract: 31 -- Source: Wos